National Cancer Institute SBIR-STTR Economic Impact Study 2018 (SBIR / STTR)

Summary

• The pilot evaluation analyzed 690 NCI SBIR/STTR Phase II grant awards made between 1998 and 2010.p.2
• NCI SBIR/STTR Phase II grants generated $9.1 billion in total sales to date of products and services.p.2
• The program generated an estimated 107,918 new jobs and $8.1 billion in labor income in the U.S.p.2
• Surveyed companies raised $4.26 billion in total outside investment funding and created 45 spin-out companies.p.4
• 89% of survey respondents stated that the NCI SBIR/STTR program provided funding at a pivotal or critical moment.p.3

Key insights

1. NCI SBIR/STTR Phase II grants generated $2.9 billion in new federal, state, and local tax revenues.p.2
2. The economic survey achieved a 91% response rate across 407 companies out of 444 contacted.p.4
3. 53% of respondents stated that their technology had generated sales, royalties, and follow-on R&D funding after the Phase II award.p.4
4. The evaluation recorded $21.63 billion in total acquisition value across 101 acquired companies.p.4
5. NCI SBIR funding resulted in 247 commercialized products, with 110 products still in development.p.3
6. 65% of awards funded the development of a new treatment for a group of patients who lacked a treatment option.p.3
7. 63% of respondents stated that a university was involved in the development of the technology.p.3